Option chain shows key data for Alumina Ltd DR's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alumina Ltd DR.

Alumina Ltd DR (OTC:AWCMY) Stock, Option Chain

Alumina

AWCMY


Alcoa Corporation (NYSE:AA) is a global leader in the production of bauxite, alumina and aluminum. Alcoa Corporation’s earnings for the first quarter of 2024 were recently announced, and a net loss was reported

Alcoa Posts Q1 Loss as Aluminum Market Volatility Persists

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

ABUS

ACAD

ALEC

BKNG

BURL

CDAY

CLLS

CLXT

DESP

DISH

EXPE

FMBI

GMRE

GWPH

LLNW

LYFT

NBIX

NMFC

OCSL

OSMT

PRVL

SAGE

TRIP

TRVG

ULTA

VIPS

VRTV

ZGNX

Benzinga&#39;s Top Upgrades, Downgrades For March 6, 2020

News

Markets

Movers

Trading Ideas

AAEEF

AAVMY

ABEV

ABGSF

ABMD

ABTX

ACCFF

ACCYY

ACHV

ACNB

ACRFF

ACRGF

ACSAY

ACST

ACTG

ADMA

ADTN

ADVZF

AERI

AFLYY

AGCO

AGEEF

AGESY

AGLXY

AHFD

AHKSY

AHOTF

AICAF

AINV

AIPUY

AIRG

AIRYY

AISSF

AKO-A

AKZOY

ALDX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALEX

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLY

ALOT

ALSN

ALTM

ALXEF

ALXN

AMCR

AMHPF

AMKBF

AMKBY

AMNB

AMPH

AMRN

AMSLF

ANAT

ANGO

ANIP

Australia and New Zealand Banking Group Limited

ANZBY

ANZFF

APELY

APEX

APHA

APTS

ARCB

ARCC

ARGGY

ARGO

ARLP

ARNA

ARNGF

AROC

ARREF

ARRRF

Stocks That Hit 52-Week Lows On Friday

Alumina Ltd DR

Castellum, Inc. (the "Company") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 9,473,700 shares of common stock in a registered direct offering. The shares of common stock are being sold at an offering price of $0.38 per share.
The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.6 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions.

Offerings

Castellum Prices $3.6M Registered Direct Offering Of 9.47M Shares At $0.38/Share

The Biden administration has launched a trade investigation into Chinese-produced &#8220;legacy&#8221; semiconductors. This action, announced on Monday, could pave the way for higher U.S. tariffs on these essential components used in numerous consumer products.
What Happened: The &#8220;Section 301&#8221; investigation is slated to transition to the incoming administration of President-elect Donald Trump for completion. This could provide Trump with a chance to enforce the hefty 60% tariffs he has previously threatened on Chinese imports, Reuters reported on Monday.
Currently, a 50% U.S. tariff on Chinese semiconductors is set to begin on Jan. 1. The U.S. has also intensified export restrictions on advanced AI and memory chips to China, alongside increasing tariffs on other Chinese goods.
See Also: <a href="https://www.benzinga.com/markets/24/12/42572520/2025-housing-market-looks-like-a-year-of-struggle-for-states-like-builders-now-hold-record-inventory?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;2025 Housing Market Looks Like A Year Of Struggle For States Like …&#8217; – Builders Now Hold Record Inventory</a>
The U.S. Trade Representative&#8217;s office, led by Katherine Tai, explained that the probe seeks to shield market-driven chip producers from China&#8217;s state-driven expansion. Tai highlighted evidence of China&#8217;s attempts to dominate the semiconductor industry, similar to its strategies in other sectors.
The Biden administration will start&nbsp;accepting public comments on the&nbsp;probe on January 6, with a public hearing scheduled for March. The investigation will also evaluate the impact of these chips on critical industries, including defense and automotive sectors.
Why It Matters: This latest probe is part of a broader strategy by the Biden administration to curb China&#8217;s influence in the semiconductor industry. Earlier this month, the administration <a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides">implemented its third crackdown</a> on China&#8217;s semiconductor sector within three years, citing national security concerns. This initiative imposed export restrictions on 140 Chinese entities, including chip equipment manufacturers such as Naura Technology Group, targeting advanced memory chips and chipmaking tools. As a result, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) saw its stock trade lower due to potential impacts on its sales in China.
In response, China swiftly retaliated by tightening <a href="https://www.benzinga.com/news/global/24/12/42303132/china-retaliates-against-us-chip-sanctions-tightens-mineral-exports">controls on critical minerals</a> used in chip manufacturing, such as gallium, germanium, and antimony. These materials are crucial for advanced electronics and defense applications. The Chinese Ministry of Commerce justified these measures as necessary for national security, highlighting the escalating tensions between the two nations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42638957/warren-buffetts-timeless-advice-if-youre-gonna-do-dumb-things-because-your-stock-goes-down-you-shouldnt-own-a-stock-at-all?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett's Timeless Advice For Investing $10,000: &#8216;If You're Gonna Do Dumb Things Because Your Stock At All&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Global

Tech

General

NVDA

Biden Administration Initiates Trade Probe On Chinese 'Legacy' Chips

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold.

MESO

Jefferies Downgrades Mesoblast to Hold

Despegar.com, Corp. (NYSE:<a href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) ("Despegar" or the "Company"), Latin America's leading travel technology company, today announced that it has entered into a definitive merger agreement ("the Agreement") to be acquired by Prosus (Euronext: PRX), a leading global technology company for $19.50 per share in an all cash transaction (the "Transaction"), representing an enterprise value of approximately $1.7 billion for Despegar.
The transaction price represents a premium of approximately 34% over the volume weighted average price of Despegar's share price for the 90 trading days ending on December 20, 2024.
Despegar's Board of Directors has approved the Agreement and has resolved to recommend that Despegar shareholders vote in favor of the adoption of the Agreement and the approval of the merger contemplated thereby. This approval follows the unanimous recommendation of a transaction committee of the Board of Directors comprised solely of independent directors that was formed in connection with the transaction

Despegar to Be Acquired by Prosus for $1.7B in Cash Deal

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) from Hold to Hold.

Reiteration

LXRX

Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold

Compass Point analyst Dominick Gabriele initiates coverage on NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announces Price Target of $57.

Price Target

NATL

Compass Point Initiates Coverage On NCR Atleos with Buy Rating, Announces Price Target of $57

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

ACRS

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").
OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.

Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.

Biotech

Health Care

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."

Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

Alcoa to buy Australia's Alumina in $2.2B all-stock deal

Biggest stock movers today: Alcoa, Domino's Pizza, Li Auto, Intuitive Machines, and more

Alumina Limited 2023 Q4 - Results - Earnings Call Presentation

Alcoa's Purchase Of Alumina Limited: The Market Is Right On This One

Alumina Limited (AWCMF) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Manufacturing remains a big part of America&rsquo;s economy. The U.S. today is the <a href="https://www.themanufacturer.com/us-manufacturing-statistics/">second largest manufacturer</a> in the world after China. According to data from <a href="https://nam.org/manufacturing-in-the-united-states/">The National Association of Manufacturers</a>, the manufacturing sector accounts for 10% of U.S. gross domestic product (GDP), employs 13 million people, and generates $1.6 trillion a year through exports of manufactured goods to other parts of the world. 



Americans employed in the manufacturing sector earn an average annual salary of $98,846 and 93% of them have access to healthcare benefits through their employer. More than half (53%) of all private sector research and development (R&amp;D) spending in the U.S. occurs in the manufacturing sector. And despite perceptions that manufacturing is in decline, projections are that four million net new jobs within the industry will be created by 2030. 



With its economic importance in mind, we offer the top three manufacturing stocks to buy in March 2024. 



<h2>General Electric (GE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ge1600-300x169.jpg" alt="Company breakups: The General Electric GE logo on a building"><div>Source: Sundry Photography / Shutterstock.com</div></div>General Electric (NYSE:<a href="https://investorplace.com/stock-quotes/ge-stock-quote/">GE</a>) is staging one of the great American comebacks. After languishing for more than a decade and being labeled a &ldquo;value trap&rdquo; by many analysts, GE stock has caught fire once again. The conglomerate that manufactures everything from airplane engines to wind turbines has seen its <a href="https://www.forbes.com/sites/qai/2023/10/25/ge-reports-stellar-earnings-ahead-of-breaking-into-two-companies/?sh=3e6b7b8039e6">share price rise 85%</a> in the last 12 months, including a 28% gain so far in 2024. Its quite a turnaround for a company and stock that many people had written off. 



The resurrection of GE stock comes as the company continues to break itself into separate publicly traded businesses. General Electric completed the separation of its healthcare business last year and plans to <a href="https://www.barrons.com/articles/buy-ge-stock-price-pick-ceo-larry-culp-8ce1498c">spinoff its energy business</a> into a separate company this April. <a href="https://www.barrons.com/articles/ge-aerospace-vernova-stock-price-valuation-34a9bf6d">The break-up</a> appears to be helping. 



General Electric recently reported fourth quarter 2023 financial results that beat estimates, announcing earnings of $1.03 per share, which was higher than the 91 cents expected by analysts. Revenue rose 15% to $19.42 billion, beating forecasts of $17.67 billion. Demand remains strong in its jet engine segment.



<h2>Alcoa (AA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/shutterstock_1329501965-min-300x169.jpg" alt="alcola stock"><div>Source: Daniel J. Macy / Shutterstock.com</div></div>Investors looking for a buy-the-dip candidate should consider U.S. aluminum giant Alcoa (NYSE:<a href="https://investorplace.com/stock-quotes/aa-stock-quote/">AA</a>). While the Pittsburgh-based manufacturer&rsquo;s stock has struggled in recent years, things are looking up with its recently announced offer to <a href="https://www.reuters.com/markets/deals/us-aluminium-maker-alcoa-makes-22-bln-offer-australias-alumina-2024-02-25/">buy rival Australian aluminum producer</a> Alumina (OTC:<a href="https://investorplace.com/stock-quotes/awcmy-stock-quote/">AWCMY</a>) for $2.21 billion. Alcoa says that the acquisition will increase its share of the global markets for both alumina and bauxite. Alcoa already has a partnership in place with Alumina.



Alcoa is buying Alumina in an all-stock deal. Alumina&rsquo;s board of directors has recommended that its shareholders support <a href="https://www.baystreet.ca/commodities/7009/Alcoa-Makes-22-Billion-Offer-For-Australias-Alumina">the friendly takeover</a>. The acquisition will give Alumina greater access to both alumina and bauxite, the key ingredients used in the manufacture of the metal aluminum, which is in demand as the world transitions away from fossil fuels. 



The Alumina takeover comes as AA stock has declined nearly 50% over the last 12 months, making the shares look cheap at current levels. 



<h2>Taiwan Semiconductor Manufacturing Co. (TSM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/tsmc1600-2-300x169.png" alt="Taiwan Semiconductor, TSMC (TSM) on phone screen stock image."><div>Source: sdx15 / Shutterstock.com</div></div>Now for a technology manufacturer. Taiwan Semiconductor Manufacturing Co. (NYSE:<a href="https://investorplace.com/stock-quotes/tsm-stock-quote/">TSM</a>) is the world&rsquo;s <a href="https://www.tomshardware.com/tech-industry/tsmc-is-now-the-worlds-largest-semiconductor-maker-by-revenue-beating-intel-and-samsung-analyst">largest manufacturer of microchips</a> and semiconductors. By most accounts, TSMC, as the company is known, makes three-quarters (75%) of all the microchips in the world. Chips that are used to power everything from artificial intelligence chatbots to refrigerators and cars. The company&rsquo;s strategic importance to the global economy cannot be understated. 



Given the demand for microchips, which is largely being fueled by AI, TSM stock is having a moment. Year-to-date, the company&rsquo;s share price is up 36%. Through 12 months, the stock has risen 54%. This as TSMC expands beyond its home market of Taiwan. The company just opened its first <a href="https://www.cnbc.com/2024/02/26/tsmc-opens-new-plant-in-japan-as-it-diversifies-away-from-taiwan.html#:~:text=TSMC%20opened%20its%20first%20chip,by%20the%20end%20of%202024.">microchip plant in Japan</a>, a 45,000 square meter, state-of-the-art manufacturing center. 



TSMC is also building two new fabrication plants in Arizona at a cost of $40 billion that&rsquo;s aimed at meeting America&rsquo;s microchip demand.



On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
<div>Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/the-top-3-manufacturing-stocks-to-buy-in-march-2024/">The Top 3 Manufacturing Stocks to Buy in March 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Top 3 Manufacturing Stocks to Buy in March 2024

Alumina agrees to $2.2B all-stock buyout offer from Alcoa

In a report released today, Paul McTaggart from Citi maintained a Hold rating on Alumina Limited (AWC – Research Report). The company's shares open...

Comments

Alumina Ltd DR

Alumina Ltd DR (AWCMY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga